| Autor: |
Yang Ou, Shengjia Sun, Haiming Shi, Jianfeng Luo, Xinping Luo, YunZhi Shen, Yufei Chen, Zhidong Zhu, Xiaojin Liu, Weihu Fan, Wei Shen |
| Rok vydání: |
2019 |
| Předmět: |
|
| DOI: |
10.21203/rs.2.17237/v1 |
| Popis: |
Percutaneous coronary intervention (PCI) can cause myocardial injury or myocardial infarction. There is unmet need to reduce incidence or severity of PCI related myocardial injury or myocardial infarction. This study is to evaluate the protective effects of salvianolate on PCI related myocardial injury or myocardial infarction after elective PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients. Methods We enrolled patients with NSTE-ACS who underwent elective PCI. The patients were randomly assigned to the salvianolate group or the control group. The incidence and the severity of PCI related myocardial injury or myocardial infarction, in addition to major adverse cardiac events (MACEs) during one year follow-up after PCI were studied between the two groups. We also performed a multivariate logistic regression analysis to determine the independent factors for PCI related myocardial injury or myocardial infarction after elective PCI. Results Compared with the control group, salvianolate treatment reduced the incidence of PCI related severe myocardial injury or myocardial infarction (11.7% vs 26.5%, p = 0.035). The rate of MACEs or all-cause death within one month or one year after the procedure was not significantly different between the two groups. Conclusions Periprocedural treatment with salvianolate reduces the incidence of PCI related severe myocardial injury or myocardial infarction, although it does not influence clinical prognosis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
